2.68
-0.11(-3.94%)
Currency In USD
| Previous Close | 2.79 |
| Open | 2.81 |
| Day High | 2.82 |
| Day Low | 2.68 |
| 52-Week High | 3.59 |
| 52-Week Low | 1.54 |
| Volume | 387,875 |
| Average Volume | 563,141 |
| Market Cap | 250.11M |
| PE | -9.57 |
| EPS | -0.28 |
| Moving Average 50 Days | 2.44 |
| Moving Average 200 Days | 2.44 |
| Change | -0.11 |
If you invested $1000 in Stereotaxis, Inc. (STXS) 10 years ago, it would be worth $4,466.67 as of January 18, 2026 at a share price of $2.68. Whereas If you bought $1000 worth of Stereotaxis, Inc. (STXS) shares 5 years ago, it would be worth $534.93 as of January 18, 2026 at a share price of $2.68.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter
GlobeNewswire Inc.
Jan 06, 2026 1:01 PM GMT
ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U.S. Food and Drug Administration (FDA) approval f
Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 24, 2025 1:58 PM GMT
ST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the company will participate in the Piper Sandler 37th An
GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearance
GlobeNewswire Inc.
Nov 10, 2025 9:05 PM GMT
ST. LOUIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received U.S. Food and Drug Administration 510(k) clea